Aviso Financial Inc. Has $1.07 Million Stake in IQVIA Holdings Inc. $IQV

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aviso Financial Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 95.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,078 shares of the medical research company's stock after selling 123,389 shares during the quarter. Aviso Financial Inc.'s holdings in IQVIA were worth $1,072,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. American National Bank & Trust acquired a new position in IQVIA in the first quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC boosted its holdings in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new position in shares of IQVIA during the first quarter valued at $33,000. Finally, ST Germain D J Co. Inc. boosted its holdings in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on IQV shares. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the company from $260.00 to $160.00 in a report on Friday, April 25th. Redburn Partners set a $188.00 price objective on shares of IQVIA in a report on Friday, May 23rd. Cowen reaffirmed a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

IQVIA Price Performance

IQVIA stock traded up $5.5970 during midday trading on Friday, hitting $190.9870. The company's stock had a trading volume of 1,619,418 shares, compared to its average volume of 1,441,272. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The stock's 50-day moving average price is $173.70 and its 200-day moving average price is $168.51. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a market capitalization of $32.47 billion, a PE ratio of 27.64, a price-to-earnings-growth ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.